The antiviral drug remdesivir reduces the time to recovery in COVID-19 patients
These are the first results of a global clinical trial in which the Hospital Clinic and ISGlobal participate.
These are the first results of a global clinical trial in which the Hospital Clinic and ISGlobal participate.
Researchers from the Respiratory biophysics and bioengineering IDIBAPS research group, the Biophysics and Bioengineering Unit of the UB and the CIBER1
SARS-CoV-2 is a virus that affects people with respiratory diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosi1
The prophylactic and serological studies will be performed on healthcare workers at Hospital Clínic of Barcelona.